Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 10/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 10/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 10/20 | 0.55 |
| ▸ | PRKAB2 | O43741 | 9/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.54 |
| ▸ | PRKAG3 | Q9UGI9 | 9/20 | 0.54 |
| ▸ | PRKAG2 | Q9UGJ0 | 9/20 | 0.54 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.47 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.47 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11911444 | 0.88 | PRKAG1 (0.67) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL23029783 | 0.88 | PRKAG1 (0.54) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL28206086 | 0.84 | MAP2K4 (0.64) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL13245137 | 0.84 | KDM4E (0.60) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL27992673 | 0.82 | GABRA1 (0.56) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL1141650 | 0.80 | PRKAG1 (0.64) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| Hydrochloric Acid SCHEMBL1141438 | 0.79 | PRKAG1 (0.63) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL1406065 | 0.79 | MAP2K4 (0.61) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL1690470 | 0.78 | JAK2 (0.55) | KIF11JAK2JAK1 | |
| SCHEMBL23108266 | 0.78 | HAO1 (0.64) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766886-B2 | Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190225599-A1 | RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE MEDICINE INC (US) | 2019-07-25 | — | — | US | disclosed |
| US-10189827-B2 | Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180141937-A1 | RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-8466295-B2 | Thiophene derivatives as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-8410155-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-8163749-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | disclosed |
| US-7842708-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| US-20100022506-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7626039-B2 | Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | disclosed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189827-B2 | Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof | RARA, RARB, RXRA | PRKAG1 189/4885PRKAA1 564/4885PRKAB1 318/4885 |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | PRKAG1 3475/4885PRKAA1 2288/4885PRKAB1 3201/4885 |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | TFPI, F12, F11 | PRKAG1 4458/4885PRKAA1 3318/4885PRKAB1 4069/4885 |
| US-20180141937-A1 | RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF | RARA, RARB, RXRA | PRKAG1 189/4885PRKAA1 564/4885PRKAB1 318/4885 |
| US-10766886-B2 | Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof | RARA, RARB, RXRA | PRKAG1 189/4885PRKAA1 564/4885PRKAB1 318/4885 |
| US-20190225599-A1 | RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF | RARA, RARB, RXRA | PRKAG1 189/4885PRKAA1 564/4885PRKAB1 318/4885 |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | TFPI, F11, F12 | PRKAG1 4375/4885PRKAA1 2283/4885PRKAB1 3961/4885 |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | PRKAG1 3923/4885PRKAA1 2690/4885PRKAB1 3653/4885 |
| US-20100022506-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | PRKAG1 3475/4885PRKAA1 2288/4885PRKAB1 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.